Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Past and present cosmetic iris implants: many perils and little progress

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Ocular Pathologies

Session Date/Time: Tuesday 08/09/2015 | 16:30-18:00

Paper Time: 16:36

Venue: Room 1

First Author: : A.Mansour LEBANON

Co Author(s): :    J. Saadeh   M. Ghabra   D. Palmar   M. ElMallah   A. Milki        

Abstract Details


Numerous cases of ocular morbidity following New Colorâ„¢ cosmetic iris implants in Panama have included the following complications: corneal decompensation, uveitis, hyphema, glaucoma, and cataract. Since then other companies have sprung up in India, Jordan, Lebanon, Mexico, Turkey, and Tunisia that claim to be implanting a newer and safe type of implant (Bright Ocular). Little is known about this implant as there is no published medical literature. We present 4 subjects who had ocular morbidity with 3 types of implants: old models that include New Color, Human Optics; and the newest Bright Ocular.


Tertiary clinics in 4 countries.


We present 4 healthy young Caucasian subjects that underwent cosmetic iris implants (in Tunisia, Lebanon, Syria, and Panama) and developed glaucoma uveitis (2 old implants) or chronic mild to moderate anterior nongranulomatous uveitis (Bright Ocular).


The patients with the old models developed glaucoma and uveitis requiring several surgeries including explantation. Visual acuity, intraocular pressure, corneal and lens clarity were normal with the Bright Ocular implant in 2 cases. Topical corticosteroid controlled the uveitis partially but surgical removal was necessary. Anterior OCT revealed the implant abutting the peripheral iris.


Old models of cosmetic iris implants are notorious for ocular morbidity. The newest model BrightOcular with its patented design has made much progress but this device still suffer from chronic uveitis and patients need to be controlled by corticosteroid and ultimately require removal.

Financial Interest:


Back to previous